KRAS and pancreatic neoplasm: The results of 4-1BB/OX-40 upregulation, CD107a upregulation, and IFN-γ/TNF-α secretion showed that IFN-γ priming, but not IFN-α2b priming, enhanced the selective recognition of TCR-001–transduced allogeneic T cells against most of the human pancreatic cancer organoids with natural KRAS G12V mutation and HLA-A*11:01 expression (Figure 7, D–F).